Long-term polyclonal and multilineage engraftment of methylguanine methyltransferase P140K gene-modified dog hematopoietic cells in primary and secondary recipients

Blood

Volumn 113, Issue 21, 2009, Pages 5094-5103

  Beard, Brian C ^a   Sud, Reeteka ^a   Keyser, Kirsten A ^a   Ironside, Christina ^a   Neff, Tobias ^a   Gerull, Sabine ^a   Trobridge, Grant D ^a,b   Kiem, Hans Peter ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 O BENZYLGUANINE; CARMUSTINE; CYCLOSPORIN; GRANULOCYTE COLONY STIMULATING FACTOR; LEUKOCYTE ANTIGEN; METHYLGUANINE METHYLTRANSFERASE P140K; METHYLTRANSFERASE; STEM CELL FACTOR; TEMOZOLOMIDE; UNCLASSIFIED DRUG; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE;

ALLOTRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOTRANSPLANTATION; CELL LINEAGE; CELL SELECTION; CONTROLLED STUDY; DNA MODIFICATION; DOG; ENGRAFTMENT; GENE ACTIVATION; GENE OVEREXPRESSION; GENE THERAPY; GENETIC TRANSCRIPTION; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL; LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; PROTO ONCOGENE; PROVIRUS; TRANSCRIPTION INITIATION SITE; VIRUS DNA CELL DNA INTERACTION; ANIMAL; GENE VECTOR; GENETICS; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METABOLISM; METHODOLOGY; RETROVIRUS;

ANIMALS; CELL LINEAGE; DOGS; GENE THERAPY; GENETIC VECTORS; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; RETROVIRIDAE;

EID: 67149106145     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-09-176412     Document Type: Article

References (58)

1. Neff T, Beard BC, Kiem H-P. Survival of the fittest: in vivo selection and stem cell gene therapy (review). Blood. 2006;107:1751-1760. (Pubitemid 43289350)
2. Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med. 2002;346:1185-1193. (Pubitemid 34984579)
3. Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002;296:2410-2413. (Pubitemid 34734219)
4. Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006;12:401-409.
5. Trobridge G, Beard BC, Kiem H-P. Hematopoietic stem cell transduction and amplification in large animal models. Hum Gene Ther. 2005;16:1355-1366. (Pubitemid 41829011)
6. Sorrentino BP. Gene therapy to protect haematopoietic cells from cytotoxic cancer drugs (review). Nat Rev Cancer. 2002;2:431-441.
7. Allay JA, Galipeau J, Blakley RL, Sorrentino BP. Retroviral vectors containing a variant dihydrofolate reductase gene for drug protection and in vivo selection of hematopoietic cells. Stem Cells. 1998;16(suppl 1):223-233.
8. Sorrentino BP, Brandt SJ, Bodine D, et al. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science. 1992;257:99-103.
9. Rattmann I, Kleff V, Sorg UR, et al. Gene transfer of cytidine deaminase protects myelopoiesis from cytidine analogs in an in vivo murine transplant model. Blood. 2006;108:2965-2971. (Pubitemid 44776933)
10. Neff T, Beard BC, Peterson LJ, Anandakumar P, Thompson J, Kiem H-P. Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy. Blood. 2005;105:997-1002. (Pubitemid 40170867)
11. Neff T, Horn PA, Peterson LJ, et al. Methylguanine methyltransferase- mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model. J Clin Invest. 2003;112:1581-1588. (Pubitemid 38056284)
12. Sawai N, Zhou S, Vanin EF, Houghton P, Brent TP, Sorrentino BP. Protection and in vivo selection of hematopoietic stem cells using temozolomide, O6-benzylguanine, and an alkyltransferase-expressing retroviral vector. Mol Ther. 2001;3:78-87.
13. Davis BM, Koc ON, Gerson SL. Limiting numbers of G156AO6-methylguanine- DNA methyltransferase-transduced marrow progenitors repopulate nonmyeloablated mice after drug selection. Blood. 2000;95:3078-3084.
14. Davis BM, Reese JS, Koc ON, Lee K, Schupp JE, Gerson SL. Selection for G156A O6-methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and protection from lethality in mice treated with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res. 1997;57:5093-5099. (Pubitemid 27498125)
15. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2003;348:255-256. (Pubitemid 36077924)
16. Board of the European Society of Gene and Cell Therapy, Executive Committee of the Clinigene Network of Excellence, Executive of the Consert Integrated Project. Case of leukemia associated with X-linked severe combined immunodeficiency gene therapy trial in London [commentary]. Hum Gene Ther. 2008;19:3-4.
17. Zhang X-B, Beard BC, Trobridge GD, et al. High incidence of leukemia in large animals after stem cell gene therapy with a HOXB4-expressing retroviral vector. J Clin Invest. 2008;118:1502-1510.
18. Seggewiss R, Pittaluga S, Adler RL, et al. Acute myeloid leukemia is associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaque. Blood. 2006;107:3865-3867. (Pubitemid 43726789)
19. Gerull S, Beard BC, Peterson LJ, Neff T, Kiem H-P. In vivo selection and chemoprotection after drug resistance gene therapy in a nonmyeloablative allogeneic transplantation setting in dogs. Hum Gene Ther. 2007;18:451-456.
20. Schmidt M, Zickler P, Hoffmann G, et al. Polyclonal long-term repopulating stem cell clones in a primate model. Blood. 2002;100:2737-2743.
21. Wu X, Li Y, Crise B, Burgess SM. Transcription start regions in the human genome are favored targets for MLV integration. Science. 2003;300:1749-1751. (Pubitemid 36712571)
22. + cells from the cord blood of ADA-deficient SCID neonates. Nat Med. 2003;9:463-468.
23. Beard BC, Keyser KA, Trobridge GD, et al. Unique integration profiles in a canine model of long-term repopulating cells transduced with gammaretrovirus, lentivirus, and foamy virus. Hum Gene Ther. 2007;18:423-434.
24. Trobridge GD, Miller DG, Jacobs MA, et al. Foamy virus vector integration sites in normal human cells. Proc Natl Acad Sci U S A. 2006;103:1498-1503. (Pubitemid 43191194)
25. Baum C, von Kalle C, Staal FJ, et al. Chance or necessity? Insertional mutagenesis in gene therapy and its consequences (review). Mol Ther. 2004;9:5-13. (Pubitemid 38208322)
26. Baum C. Insertional mutagenesis in gene therapy and stem cell biology (review). Curr Opin Hematol. 2007;14:337-342. (Pubitemid 46842807)
27. Smith AN. Hemangiosarcoma in dogs and cats. Vet Clin North Am: Small Anim Pract. 2003;33:533-552.
28. Small Animal Internal Medicine. St Louis, MO: Mosby; 1998.
29. Benjamin SA, Lee AC, Angleton GM, Saunders WJ, Keefe TJ, Mallinckrodt CH. Mortality in beagles irradiated during prenatal and postnatal development, II: contribution of benign and malignant neoplasia. Radiat Res. 1998;150:330-348.
30. Williams DA, Hsieh K, DeSilva A, Mulligan RC. Protection of bone marrow transplant recipients from lethal doses of methotrexate by the generation of methotrexate-resistant bone marrow. J Exp Med. 1987;166:210-218. (Pubitemid 17101901)
31. Mickisch GH, Licht T, Merlino GT, Gottesman MM, Pastan I. Chemotherapy and chemosensitization of transgenic mice which express the human multidrug resistance gene in bone marrow: efficacy, potency, and toxicity. Cancer Res. 1991;51:5417-5424.
32. Neff T, Blau CA. Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. Exp Hematol. 1996;24:1340-1346. (Pubitemid 26348932)
33. Takebe N, Zhao SC, Adhikari D, et al. Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene. Mol Ther. 2001;3:88-96. (Pubitemid 32509809)
34. Harkey MA, Czerwinski M, Slattery J, Kiem H-P. Overexpression of glutathione-S-transferase, MGSTII, confers resistance to busulfan and melphalan. Cancer Invest. 2005;23:19-25. (Pubitemid 40344196)
35. Pollok KE, Hartwell JR, Braber A, et al. In vivo selection of human hematopoietic cells in a xenograft model using combined pharmacologic and genetic manipulations. Hum Gene Ther. 2003;14:1703-1714.
36. Botnick LE, Hannon EC, Hellman S. Multisystem stem cell failure after apparent recovery from alkylating agents. Cancer Res. 1978;38:1942-1947. (Pubitemid 8375074)
37. Botnick LE, Hannon EC, Hellman S. Nature of the hemopoietic stem cell compartment and its proliferative potential. Blood Cells. 1979;5:195-210. (Pubitemid 9233314)
38. Botnick LE, Hannon EC, Vigneulle R, Hellman S. Differential effects of cytotoxic agents on hematopoietic progenitors. Cancer Res. 1981;41:2338-2342. (Pubitemid 11111439)
39. Dumenco LL, Warman B, Hatzoglou M, Lim IK, Abboud SL, Gerson SL. Increase in nitrosourea resistance in mammalian cells by retrovirally mediated gene transfer of bacterial O6-alkylguanine-DNA alkyltransferase. Cancer Res. 1989;49:6044-6051. (Pubitemid 19274168)
40. Allay JA, Dumenco LL, Koc ON, Liu L, Gerson SL. Retroviral transduction and expression of the human alkyltransferase cDNA provides nitrosourea resistance to hematopoietic cells. Blood. 1995;85:3342-3351.
41. Allay JA, Koc ON, Davis BM, Gerson SL. Retroviral-mediated gene transduction of human alkyltransferase complementary DNA confers nitrosourea resistance to human hematopoietic progenitors. Clin Cancer Res. 1996;2:1353-1359.
42. Dolan ME, Pegg AE, Dumenco LL, Moschel RC, Gerson SL. Comparison of the inactivation of mammalian and bacterial O6-alkylguanine-DNA alkyltransferases by O6-benzylguanine and O6-methylguanine. Carcinogenesis. 1991;12:2305-2309.
43. Gerson SL, Zborowska E, Norton K, Gordon NH, Willson JK. Synergistic efficacy of O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in a human colon cancer xenograft completely resistant to BCNU alone. Biochem Pharmacol. 1993;45:483-491. (Pubitemid 23042649)
44. Reese JS, Koc ON, Lee KM, et al. Retroviral transduction of a mutant methylguanine DNA methyltransferase gene into human CD34 cells confers resistance to O6-benzylguanine plus 1,3-bis(2-chloroethyl)-1-nitrosourea. Proc Natl Acad Sci U S A. 1996;93:14088-14093. (Pubitemid 26424250)
45. Davis BM, Roth JC, Liu L, Xu-Welliver M, Pegg AE, Gerson SL. Characterization of the P140K, PVP(138-140)MLK, and G156A O6-methylguanine-DNA methyltransferase mutants: implications for drug resistance gene therapy. Hum Gene Ther. 1999;10:2769-2778.
46. Davis BM, Encell LP, Zielske SP, et al. Applied molecular evolution of O6-benzylguanine-resistant DNA alkyltransferases in human hematopoietic cells. Proc Natl Acad Sci U S A. 2001;98:4950-4954.
47. Encell LP, Coates MM, Loeb LA. Engineering human DNA alkyltransferases for gene therapy using random sequence mutagenesis. Cancer Res. 1998;58:1013-1020.
48. Christians FC, Dawson BJ, Coates MM, Loeb LA. Creation of human alkyltransferases resistant to O6-benzylguanine. Cancer Res. 1997;57:2007-2012.
49. Christians FC, Loeb LA. Novel human DNA alkyltransferases obtained by random substitution and genetic selection in bacteria. Proc Natl Acad Sci U S A. 1996;93:6124-6128.
50. 6-(4-bromothenyl)guanine. J Gene Med. 2006;8:29-34.
51. Trobridge GD, Beard BC, Gooch C, et al. Efficient transduction of pigtailed macaque hemtopoietic repopulating cells with HIV-based lentiviral vectors. Blood. 2008;111:5537-5543.
52. Milsom MD, Jerabek-Willemsen M, Harris CE, et al. Reciprocal relationship between O6-methylguanine-DNA methyltransferase P140K expression level and chemoprotection of hematopoietic stem cells. Cancer Res. 2008;68:6171-6180.
53. Calmels B, Ferguson C, Laukkanen MO, et al. Recurrent retroviral vector integration at the Mds1-Evi1 locus in nonhuman primate hematopoietic cells. Blood. 2005;106:2530-2533.
54. Beard BC, Dickerson D, Beebe K, et al. Comparison of HIV-derived lentiviral and MLV-based gammaretroviral vector integration sites in primate repopulating cells. Mol Ther. 2007;15:1356-1365. (Pubitemid 46969874)
55. Ball CR, Pilz IH, Schmidt M, et al. Stable differentiation and clonality of murine long-term hematopoiesis after extended reduced-intensity selection for MGMT P140K transgene expression. Blood. 2007;110:1779-1787. (Pubitemid 47443888)
56. Mauch P, Constine L, Greenberger J, et al. Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy. Int J Radiat Oncol Biol Phys. 1995;31:1319-1339.
57. Neben S, Hellman S, Montgomery M, Ferrara J, Mauch P. Hematopoietic stem cell deficit of transplanted bone marrow previously exposed to cytotoxic agents. [Published erratum appears in Exp Hematol. 1993;21:398] Exp Hematol. 1993;21:156-162.
58. Abkowitz JL, Golinelli D, Guttorp P, Abkowitz JL, Golinelli D, Guttorp P. Strategies to expand transduced hematopoietic stem cells in vivo. Mol Ther. 2004;9:566-576. (Pubitemid 38578807)